1 / 13

Prometheus & Myriad

Prometheus & Myriad. The Future of Diagnostic & Gene Claims. Mercedes Meyer, Ph.D. Kevin Noonan, Ph.D. Discussion Points. A rear view of Classen and Labcorp. AIA 35 USC § 101 change. USPTO Memo Guidance March 21, 2012 The tension – McKesson & Akamai 35 U.S.C. § 287(c)

raina
Télécharger la présentation

Prometheus & Myriad

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prometheus& Myriad The Future of Diagnostic & Gene Claims Mercedes Meyer, Ph.D. Kevin Noonan, Ph.D.

  2. Discussion Points • A rear view of Classen and Labcorp. • AIA 35 USC § 101 change. • USPTO Memo Guidance March 21, 2012 • The tension – McKesson & Akamai • 35 U.S.C. § 287(c) • Smartgene – March 30, 2012

  3. More Discussion Points • The politics • The public • The stakeholders • The politician – Congresswoman Wasserman-Schultz • AIA S. 27 • The Hearings Feb. 16 & Mar. 9 • The White House, DOJ, USPTO, NIH • LDTs, CLIA, and the FDA • Stakeholders: Pharma, Consumers/Patients, Companion diagnostic manufacturers, Payers, Physicians, Regulatory, and Testing Labs

  4. Some myths on gene patents • Patents and Costs • No evidence was found demonstrating that patents accelerated or inhibited test development for certain conditions (e.g. hearing loss). • Price for genetic tests did not appear to correlate with patent status. Some for-profit providers had the same cost as not-for-profit testing providers. • Patents have been found not impede consumer utilization of the tests. • The marketplace is the driver of gene testing. • Incorrect data – the myth that 20% of the human genes are patented is false. • Whole Genome Sequencing – does not infringe a gene patent.

  5. Some more myths on gene patents Patents and Innovation No evidence for a “tragedy of the anticommons” regarding basic research >9,000 scientific journal articles on BRCA genes post-patenting “Isolated DNA” claims not infringed by genetic diagnostic testing Claims require isolation of full-length genes capable of producing encoded protein Isolation not required for genetic diagnostic tests Oligomer claims of questionable validity Gene patents do not inhibit information about genes Genetic information is not patented and gene patent claims not infringed by in silico analyses

  6. A Slippery Slope & The Future • Some (Judge Moore) voice a concern that if DNA patents are attacked there will be a slippery slope effect to capture other compounds. • Antisense, siRNA. • Proteins and peptides. • Antibodies and their fragments. • Method of treatment claims are recognized for Orange Book listings. • Companion Diagnostics.

  7. A Slippery Slope & The Future Consider these examples: Isolated chemical compound from crude oil useful as a lubricant Isolated chemical compound from a plant useful as a drug Isolated protein from an animal useful to cure/ameliorate human disease From a human?

  8. Myriad DNA Claims - Eligible?USPN 5,693,473 • 1. An isolated DNAcomprising an altered BRCA1 DNA having at least one of the alterations set forth in Tables 12A, 14, 18 or 19 with the proviso that the alteration is not a deletion of four nucleotides corresponding to base numbers 4184-4187 in SEQ. ID. NO:1.

  9. Myriad DNA Claims - Eligible?USPN 5,747,282 • 7. An isolated DNA selected from the group consisting of: • (a) a DNA having the nucleotide sequence set forth in SEQ ID NO:1 having T at nucleotide position 4056; • (b) a DNA having the nucleotide sequence set forth in SEQ ID NO:1 having an extra C at nucleotide position 5385; • (c) a DNA having the nucleotide sequence set forth in SEQ ID NO: 1 having G at nucleotide position 5443; and, (d) a DNA having the nucleotide sequence set forth in SEQ ID NO:1 having 11 base pairs at nucleotide positions 189-199 deleted.

  10. Is Licensing “THE” Issue? Single Providers Myriad / BRCA1 & 2 Canavan Disease – Miami Children’s Hospital Multiple Providers Long QT Syndrome has two providers with separate blocking patents Hearing loss – multiple providers for patents and unpatented genes Hereditary hemochromatosis – multiple LDTs; no IP impact Alzheimer’s Disease Lynch Syndrome (HNPCC) Familial adenomatous polyposis (FAP) Spinocerebellar ataxia

  11. Myriad Internationally Gene Patent Attacks Globally

  12. International Stance • Canada – Myriad attacked the government. Today, Myriad’s patents are primarily ignored. • Europe – Opposed by Institut Curie. • UK – provides BRCA testing without payment to Myriad. • Australia – the government investigated and came close to banning gene patents. • Japan – exclusively licensed the rights to Falco.

  13. Questions? Mercedes K. Meyer, Ph.D. Drinker Biddle & Reath LLP Washington, DC 20005 Kevin E. Noonan, Ph.D. McDonnell Boehnen Hulbert & Berghoff LLP Chicago, IL 60606

More Related